EA201170028A1 - СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α - Google Patents

СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α

Info

Publication number
EA201170028A1
EA201170028A1 EA201170028A EA201170028A EA201170028A1 EA 201170028 A1 EA201170028 A1 EA 201170028A1 EA 201170028 A EA201170028 A EA 201170028A EA 201170028 A EA201170028 A EA 201170028A EA 201170028 A1 EA201170028 A1 EA 201170028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tnf
multispecific
binding proteins
target binding
fusion proteins
Prior art date
Application number
EA201170028A
Other languages
English (en)
Inventor
Алан Кейт Лофквист
Кендалл Марк Молер
Питер Роберт Баум
Питер Армстронг Томпсон
Линда Мишер
Original Assignee
Эмерджент Продакт Дивелопмент Сиэтл, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмерджент Продакт Дивелопмент Сиэтл, Ллс filed Critical Эмерджент Продакт Дивелопмент Сиэтл, Ллс
Publication of EA201170028A1 publication Critical patent/EA201170028A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)

Abstract

Согласно настоящему изобретению предложен мультиспецифичный гибридный белок, состоящий из домена - антагониста TNF-α и другого связывающего домена - антагониста гетерологичной мишени, например UIL-6, RANKL, IL-7, IL-17A/F, TWEAK, CSF-2, IGF1, IGF2 или BLyS/APRIL, или агониста гетерологичной мишени, например IL-10. Указанный мультиспецифичный гибридный белок также может содержать промежуточный домен, разделяющий указанные связывающие домены и способствующий образованию димеров. Согласно настоящему изобретению также предложены полинуклеотиды, кодирующие указанные мультиспецифические гибридные белки, композиции, содержащие указанные мультиспецифические гибридные белки, и способы применения мультиспецифических гибридных белков и композиций, содержащих указанные белки.
EA201170028A 2008-07-02 2009-07-02 СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α EA201170028A1 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US13409708P 2008-07-02 2008-07-02
US13409508P 2008-07-02 2008-07-02
US13409908P 2008-07-02 2008-07-02
US13410108P 2008-07-02 2008-07-02
US13410008P 2008-07-02 2008-07-02
US13409608P 2008-07-02 2008-07-02
US13409808P 2008-07-02 2008-07-02
US18009709P 2009-05-20 2009-05-20
PCT/US2009/049603 WO2010003108A2 (en) 2008-07-02 2009-07-02 TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS

Publications (1)

Publication Number Publication Date
EA201170028A1 true EA201170028A1 (ru) 2011-12-30

Family

ID=41051379

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170028A EA201170028A1 (ru) 2008-07-02 2009-07-02 СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α

Country Status (13)

Country Link
US (1) US20110152173A1 (ru)
EP (1) EP2310410A2 (ru)
JP (1) JP2011526792A (ru)
KR (1) KR20110044991A (ru)
CN (1) CN102171247A (ru)
AU (1) AU2009266863A1 (ru)
BR (1) BRPI0914005A2 (ru)
CA (1) CA2729749A1 (ru)
EA (1) EA201170028A1 (ru)
IL (1) IL210264A0 (ru)
MX (1) MX2011000041A (ru)
NZ (1) NZ590668A (ru)
WO (1) WO2010003108A2 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN102719444B (zh) 2006-09-01 2016-12-14 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
CA2729747A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Il6 immunotherapeutics
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
EA032828B1 (ru) * 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr
EP2516467A2 (en) * 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제
KR101004363B1 (ko) * 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제
US9096669B2 (en) * 2010-09-30 2015-08-04 Chengdu Kanghong Biotechnologies Co., Ltd. Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same
SI2673373T1 (sl) * 2011-02-08 2019-03-29 Medimmune, Llc Protitelesa, ki specifično vežejo alfa toksin Staphylococcus aureus in postopki uporabe
JP6158090B2 (ja) * 2011-10-31 2017-07-05 ダニエル・ジェイ・カポン 非ペプチドヒンジ部含有フレキシブル抗体様分子
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
JP2015505843A (ja) 2011-12-15 2015-02-26 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
MX366813B (es) 2012-04-20 2019-07-25 Aptevo Res & Development Llc Polipeptidos de enlace cd3.
CN104583239B (zh) 2012-05-10 2018-09-18 生物蛋白有限公司 多特异单克隆抗体
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
CN103060274B (zh) * 2012-12-28 2013-12-11 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
EP3062818B1 (en) * 2013-11-01 2019-09-11 IBC Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
KR20180050321A (ko) 2015-08-07 2018-05-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
CN113897371A (zh) 2015-10-29 2022-01-07 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
EP3293293A1 (en) * 2016-09-08 2018-03-14 Italfarmaco SpA Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
BR112021001214A2 (pt) 2018-07-24 2021-04-27 Medimmune, Llc anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus
AU2019357983A1 (en) 2018-10-09 2021-05-27 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
US20220242962A1 (en) 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
MX2022008654A (es) 2020-01-13 2022-08-18 Aptevo Res & Development Llc Formulaciones para productos terapeuticos proteicos.
CA3197104A1 (en) * 2020-11-11 2022-05-19 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
CN112451670B (zh) * 2020-11-25 2024-01-02 沣潮医药科技（上海）有限公司 异位内膜治疗的组合物和预后检测试剂盒
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc CD3-binding bispecific and heterodimeric antibodies to PSMA
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
CN117136196A (zh) * 2022-03-03 2023-11-28 上海赛金生物医药有限公司 一种重组融合蛋白的制剂
WO2023178306A2 (en) * 2022-03-18 2023-09-21 Fab Biopharma, Inc. Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
JP3887011B2 (ja) * 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2446734A1 (en) * 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DE10148217C1 (de) * 2001-09-28 2003-04-24 Bosch Gmbh Robert Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine
ATE509032T1 (de) * 2002-02-13 2011-05-15 Ludwig Inst For Cancer Res Ltd Chimerizierte gm-csf antikörper
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
WO2005118642A2 (en) * 2004-06-01 2005-12-15 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
KR20080022539A (ko) * 2004-10-12 2008-03-11 앰프로틴 코포레이션 키메라 단백질
EP1819731A4 (en) * 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006105021A2 (en) * 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
DK1888643T3 (en) * 2005-05-18 2015-01-05 Morphosys Ag Anti-GM-CSF antibodies as well as their uses
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
CN101370525B (zh) * 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5259423B2 (ja) * 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
CA2729747A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Il6 immunotherapeutics
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
US20110158995A1 (en) * 2008-07-28 2011-06-30 Renault S.A.S Multi-Specific Binding Proteins Targeting B Cell Disorders
EP3281955A1 (en) * 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
EA032828B1 (ru) * 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr

Also Published As

Publication number Publication date
CN102171247A (zh) 2011-08-31
AU2009266863A1 (en) 2010-01-07
MX2011000041A (es) 2011-05-23
WO2010003108A3 (en) 2010-02-25
BRPI0914005A2 (pt) 2015-11-17
JP2011526792A (ja) 2011-10-20
NZ590668A (en) 2012-12-21
KR20110044991A (ko) 2011-05-03
IL210264A0 (en) 2011-03-31
EP2310410A2 (en) 2011-04-20
WO2010003108A2 (en) 2010-01-07
US20110152173A1 (en) 2011-06-23
CA2729749A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
EA201170028A1 (ru) СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
NZ592420A (en) Cd86 antagonist multi-target binding proteins
EA201170031A1 (ru) СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ ПО ОТНОШЕНИЮ К TGF-β
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
EA201001223A1 (ru) Стабилизированные белковые композиции
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
EA201300330A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
EA201001139A1 (ru) УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB
EA201290254A1 (ru) Антагонисты il-17a
IS8016A (is) Prótín sem bindast viðtaka NOGO
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
MX2007010349A (es) Composiciones y metodos para clasificar muestras biologicas.
WO2014144573A3 (en) Multimerization technologies
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
DK1966244T3 (da) Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
TW200731997A (en) Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
EA201891500A3 (ru) Белки, связывающиеся с cgrp-рецепторами человека
WO2006073443A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2005005462A3 (en) Blys antagonists and uses thereof
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2004005890A3 (en) Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof